A balanced cortisol keeps you alert, and your BP and sugar steady. Trouble starts when it rises and stays high for too long.

Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex's portfolio - PALSONIFY, Crinetics' recently launched, first ...

Key Points Interested in Vertex Pharmaceuticals Incorporated? Here are five stocks we like better. Vertex Pharmaceuticals ...

In a small cohort of patients with Cushing’s disease, most had their urinary free cortisol normalized after being ...

Vertex Pharma to buy Crinetics Pharmaceuticals for $10 billion: Boston Wednesday, July 8, 2026, 14:00 Hrs [IST] Vertex Pharmaceuticals Incorporated, a global biotechnology company ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals for $10 billion cash, in a deal that would expand the ...

Vertex Pharmaceuticals Incorporated’s $10B Crinetics Pharmaceuticals, Inc. buy adds PALSONIFY & a Phase 3 CAH asset. Click ...

Vertex Pharmaceuticals to acquire Crinetics (CRNX) for $10 billion in all-cash deal at $85 per share, gaining key ...

The transaction's two focuses, Palsonify and atumelnant, have combined peak sales potential of more than $5 billion, Vertex ...

At ENDO 2026, the annual meeting of the Endocrine Society, researchers reported that measuring adrenocorticotropic hormone ...

Vertex Pharma has made the largest acquisition in its history, agreeing to buy Crinetics Pharma for around $10 billion in a ...